Work

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

Year: 2019

Type: article

Study design: Study Protocol

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz437.061

Authors: J.C.-H. Yang, B. Ellers-Lenz, J. Straub, A. Johne, Y.-L. Wu

Institutions: National Taiwan University Hospital, Merck Healthcare KGaA, Darmstadt (Germany), Merck KGaA, Darmstadt (Germany), Guangdong Provincial People's Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Ono Pharmaceutical, Daiichi Sankyo Europe

OpenAlex ID: W2991074819

FWCI: 2.595

Cites:

Cited by: 15

Related to: 10